Semaglutide  (Synonyms: 司美格鲁肽)

Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer^{[1][2][3][4][5]}.

1. 抗 Aβ_25-35 损伤实验：
Semaglutide (1-100 nM；24 h) 显著提高 SH-SY5Y 细胞的存活率，增加 LC3II、Atg7、Beclin-1 和 P62 等自噬相关蛋白表达，抑制 Bax 并上调 Bcl-2，通过增强自噬、抑制凋亡并保护神经细胞^[1][2]。
2. 口腔鳞状细胞癌 (OSCC) 细胞实验：
Semaglutide (5-40 μM；48 h) 剂量依赖性抑制 Cal27 和 HSC4 细胞的增殖、迁移及侵袭，上调 E-cadherin 并下调 Vimentin，激活 P38 MAPK 信号通路 (p-P38 表达增加)，诱导细胞凋亡^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

此产品非口服制剂，进行动物实验时，可选择皮下或者腹腔注射。
口腔鳞状细胞癌 (OSCC) 移植瘤模型
Semaglutide (3 μmol/kg；皮下注射；每周 3 次；3 周) 显著抑制裸鼠口腔鳞状细胞癌 (OSCC) 移植瘤模型的肿瘤体积增长，下调增殖标志物 Ki67 和 PCNA，上调促凋亡蛋白 Bax 并下调抗凋亡蛋白 Bcl-xL，通过激活 P38 MAPK 通路诱导肿瘤细胞凋亡^[3]。
慢性 MPTP 诱导的帕金森病模型
Semaglutide (25 nmol/kg；腹腔注射；每 2 天 1 次；30 天) 改善小鼠慢性 MPTP 诱导的帕金森病模型及其运动功能障碍，增加黑质酪氨酸 (TH) 阳性神经元数量，减少 α-突触核蛋白聚集及胶质细胞活化，降低氧化应激标志物 4-HNE 水平^[4]。
代谢功能障碍相关脂肪性肝病 (MASLD) 模型
Semaglutide (25 μg/kg/周+100 μg/kg/周；皮下注射；每周 1 次；11 周) 在小鼠代谢功能障碍相关脂肪性肝病 (MASLD) 模型中，降低小鼠体重、血糖及血清肝酶 (ALT、AST、AP)，减少肝内甘油三酯沉积，改善肝脂肪变性及肝细胞气球样变，下调从头脂肪生成标志物 Acaca 和 Scd1^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

4113.58

C₁₈₇H₂₉₁N₄₅O₅₉

910463-68-2

固体

White to off-white

His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-{C18 diacid-γ-Glu-(AEEA)2-Lys}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

H-{Aib}-EGTFTSDVSSYLEGQAA-{C18 diacid-γ-Glu-(AEEA)2-Lys}-​​​EFIAWLVRGRG

索玛鲁肽； 司美格鲁肽； 司马鲁肽

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

• [1]. Chang YF, et al. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020 Nov;81:234-239.  [Content Brief]

  [2]. Liu DX, et al. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022 Jul 13;2022:6813017.  [Content Brief]

  [3]. Wang C, et al. Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. J Cancer Res Clin Oncol. 2025 Mar 7;151(3):103.  [Content Brief]

  [4]. Zhang L, et al. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9(1):157-171.  [Content Brief]

  [5]. Soto-Catalán M, et al. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci. 2024 Mar 4;25(5):2961.  [Content Brief]

  [6]. Stephen T Buckley, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018 Nov 14;10(467):eaar7047.  [Content Brief]